Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 18/20 | 0.68 |
| ▸ | ITGAV | P06756 | 18/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6702670 | 0.99 | ITGB3 (0.68) | ITGB3ITGAVKCNH2ITGA2B | |
| SCHEMBL3232755 | 0.84 | ITGB3 (0.66) | ITGB3ITGAVITGA2B | |
| SCHEMBL6700859 | 0.84 | ITGB3 (0.70) | ITGB3ITGAV | |
| SCHEMBL3222279 | 0.84 | ITGB3 (0.69) | ITGB3ITGAV | |
| SCHEMBL3221473 | 0.80 | ITGB3 (0.65) | ITGB3ITGAVITGA2B | |
| SCHEMBL3220068 | 0.75 | ITGAV (0.45) | ITGB3ITGAVITGA2B | |
| SCHEMBL3228383 | 0.74 | ITGAV (0.46) | ITGB3ITGAVITGA2B | |
| SCHEMBL7032628 | 0.70 | ITGB3 (0.72) | ITGB3ITGAVITGA2B | |
| SCHEMBL3220109 | 0.70 | TSHR (0.49) | ITGB3ITGAVITGA2B | |
| SCHEMBL6700952 | 0.69 | TSHR (0.52) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048536-A1 | Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands | GENESTE HERVE | 2010-02-25 | — | — | US | disclosed |
| US-20040077638-A1 | Novel integrin receptor antagonists | BASF AKTIENGESELLCHAFT (DE) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048536-A1 | Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands | ITGB3, ITGAL, ITGB4 | ITGB3 1/4885ITGAV 5/4885KCNH2 1086/4885 |
| US-20040077638-A1 | Novel integrin receptor antagonists | ITGB3, ITGAV, ITGA2B | ITGB3 1/4885ITGAV 2/4885KCNH2 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.